| Detected | Trial | Change |
|---|---|---|
| 2026-06-09 | NCT07405164 Extension Study for Participants in Studies That Include Belzutifan… |
Trial sites expanded: 15 -> 20 locations |
| 2026-05-29 | NCT04542733 The Efficacy of Everolimus With Reduced-dose Tacrolimus Versus Reduced-dose Tacrolimus… |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-05-29 | NCT04542733 The Efficacy of Everolimus With Reduced-dose Tacrolimus Versus Reduced-dose Tacrolimus… |
date change Primary completion pushed: 2025-12-24 -> 2027-12-31 |
| 2026-05-29 | NCT04542733 The Efficacy of Everolimus With Reduced-dose Tacrolimus Versus Reduced-dose Tacrolimus… |
date change Completion pushed: 2026-07 -> 2028-07 |
| 2026-05-19 | NCT06428396 Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer… |
date change Completion pushed: 2028-10-07 -> 2028-12-25 |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-09 | NCT07634601 Elacestrant With Everolimus for the Treatment of Recurrent Advanced or Metastatic… | Phase 2 | Not Yet Recruiting |
| 2026-06-02 | NCT07619950 EVERolimus and LenvAtinib Versus Everolimus for Bone Sarcoma | Phase 2 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT02081755 | Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer | Carcinoma, Hepatocellular | Enrolling by Invitation |
| NCT07426484 | Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy | Cutaneous Squamous Cell Carcinoma | Not Yet Recruiting |
| NCT05252585 | A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous… | Renal Angiomyolipoma | Active, Not Recruiting |
| Phase 3 | |||
| NCT05476939 | Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0 | Diffuse Intrinsic Pontine Glioma | Recruiting |
| NCT05477576 | Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET… | GEP-NET | Recruiting |
| NCT06382948 | Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer… | Advanced Breast Cancer | Recruiting |
| NCT07062965 | A Study to Learn About the Study Medicine Called PF-07248144 in Combination With… | Breast Cancer | Recruiting |
| NCT05918302 | Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor… | Neuroendocrine Tumors | Recruiting |
| NCT07405164 | Extension Study for Participants in Studies That Include Belzutifan… | Von Hippel-Lindau Disease | Recruiting |
| NCT01674140 | S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer | Breast Cancer | Active, Not Recruiting |
| NCT07407517 | Adjuvant Intensification for LAR | Breast Cancer Females | Not Yet Recruiting |
| NCT02811861 | Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of… | Renal Cell Carcinoma | Active, Not Recruiting |
| NCT02962414 | Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC… | Tuberous Sclerosis Complex | Active, Not Recruiting |
| NCT03049189 | Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients | Neuroendocrine Tumors | Active, Not Recruiting |
| NCT05306340 | A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With… | Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer | Active, Not Recruiting |
| NCT04195750 | A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal… | Carcinoma, Renal Cell | Active, Not Recruiting |
| Phase 2/3 | |||
| NCT06943755 | Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic… | Pancreatic Neuroendocrine Tumor (pNET) | Recruiting |
| NCT07165886 | Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in… | Gastroenteropancreatic Neuroendocrine Tumors | Recruiting |
| NCT07218575 | Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline Mutations | Cowden's Disease | Not Yet Recruiting |
| Phase 2 | |||
| NCT05933395 | Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor | Advanced Breast Cancer | Recruiting |
| NCT07191353 | Resistance Training and Rapamycin to Enhance Bone Formation in Postmenopausal Women | Healthy | Recruiting |
| NCT06428396 | Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer… | Metastatic Breast Cancer | Recruiting |
| NCT06280950 | Expanding Liver Transplant Immunosuppression Minimization Via Everolimus | Liver Transplant | Recruiting |
| NCT05843253 | Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG… | High Grade Glioma | Recruiting |
| NCT05773274 | Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With… | Metastatic Digestive System Neuroendocrine Tumor G1 | Recruiting |